Dr. Paul Anderson currently serves on the Board of Directors of several companies and the Chemical Heritage Foundation. In 2009, he is Chairman of the Board of Trustees of the Gordon Research Conferences. During his celebrated career at Merck, Dr. Anderson and coworkers developed TRUSOPT, the first topical carbonic anhydrase inhibitor for treating glaucoma, and ZOCOR, a frequently prescribed drug for lowering cholesterol levels. Dr. Anderson has directed extensive medicinal chemistry efforts at Merck and DuPont Pharmaceuticals Company focused on new chemotherapy for AIDS, resulting in CRIXIVAN and SUSTIVA. Dr. Anderson is the recipient of countless awards, including in 2006 the American Chemical Society recognized Dr. Anderson with its highest honor, the Priestley Medal. In addition, Dr. Anderson has served as Chairman of the Medicinal Chemistry Division of the American Chemical Society, Chairman of the Gordon Research Conference on Medicinal Chemistry, Chairman of the NIH Study Section on Bioorganic Chemistry and Natural Products, as well as being a member of the National Advisory General Medicinal Sciences Council of the National Institutes of Health and the National Research Council, Board on Chemical Sciences and Technology.